The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
The pharmaceutical industry is increasingly turning to Bayesian methods in early phase trials in an attempt to improve efficiency and enhance decision making. One reason for this growing interest is the ability of Bayesian methods to leverage relevant external information, be this historical data or expert opinion. This 1-day scientific meeting provides an opportunity to learn about some of the main techniques for incorporating historical data into study analyses using different discounting methods, and for eliciting expert prior information in situations where no or limited historical data are available.
Further updates and exact timings to the programme will be forthcoming.
Confirmed Speakers:
Nicky Best (GSK): Prior elicitation in practice: early experiences with eliciting expert beliefs to enhance decision making in drug development
Nelson Kinnersley (Roche): Practical Considerations when Eliciting Expert Beliefs for Clinical Trial Design
Nelson will share experiences gained from conducting elicitation sessions in the clinical trial domain. Aspects of preparation, training, conducting and documenting the outcomes will be described.
Tony O’Hagan (Sheffield University): Where do we need expert judgment in drug development? ... Everywhere.
Kate Ren (Sheffield University): Elicitation in clinical trial planning: time-to-event data
Beat Neuenschwander (Novartis): Using Co-Data in Early Phase Clinical Trials: Practical and Methodological Aspects
Registration on or before 23rd July
PSI Members: £100.00 (plus VAT)
Non-Members*: £140.00 (plus VAT)
Academics*: £40.00 (plus VAT)
Registration after 23rd July
PSI Members: £140.00 (plus VAT)
Non-Members*: £200.00 (plus VAT)
Academics*: £70.00 (plus VAT)
* Price includes 1 year PSI affiliate membership
Early registration is encouraged as places are limited.
Attendance at the course counts as 7.5 hours towards any CPD requirements
Many thanks to GSK
for hosting the September event.
If you would like to host a PSI one day meeting for a topic of particular
interest to you please contact: nickm@amgen.com
(Scientific Chair) PSI
Upcoming Events
PSI Introduction to Industry Training (ITIT) Course - 2026/2027
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This webinar brings together three bitesize complementary sessions to help PSI contributors create conference presentations and posters that communicate clearly and inclusively. Participants will explore how to refine their message, prepare materials effectively, and adopt practical habits that support confident, accessible delivery. A focused, supportive session designed to elevate every contribution.
Our monthly webinar series allows attendees to gain practical knowledge and skills in open-source coding and tools, with a focus on applications in the pharmaceutical industry. This month’s session, “Graphics Basics,” will introduce the fundamentals of producing graphics using the ggplot2 package.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Join our Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a webinar on the strategic role of statisticians in the Joint Clinical Assessment (JCA). The introduction of the JCA marks a new era for evidence generation and market access in Europe. As HTA requirements become more harmonized and methodologically demanding, the role of statisticians has evolved far beyond data analysis. Today, statistical expertise is central to shaping clinical development strategies, designing robust comparative evidence, and ensuring that submissions withstand the scrutiny of EU-level assessors. In this webinar, we explore how statisticians contribute strategically to successful JCA outcomes.
Statisticians in the Age of AI: On Route to Strategic Partnership
A 90-minute webinar featuring two case studies from Bayer and Roche demonstrating how statisticians successfully integrated into AI programs, followed by interactive discussion on strategies for elevating statistical expertise in the AI era.
Enhancing Clinical Study Reporting with the Estimand Framework
Join us for an insightful webinar where we explore practical strategies for applying the estimand framework in clinical study reporting. Drawing on real-world experiences and case studies, we will share recommendations to help you:
• Understand the role of estimands in improving transparency and interpretation of trial results.
• Navigate common challenges in implementing the framework during reporting.
• Apply best practices to enhance regulatory submissions, webposting in public registries (clinicaltrials.gov/CTIS), and scientific publications.
Whether you are involved in clinical trial design, data analysis, or regulatory submissions, this session will provide actionable guidance to realize the full potential of the estimand framework.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
GSK - Statistics Director - Vaccines and Infectious Disease
We are seeking an experienced and visionary Statistics Director to join our Team and lead strategic statistical innovation across GSK’s Vaccines and Infectious Disease portfolio.
As a Senior Biostatistician I at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
As a Statistical Scientist at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
We have an exciting opportunity for an Associate Director, Biostatistics to join a passionate team within Advanced Quantitative Sciences – Full Development.
: We have an exciting opportunity for an Associate Director (AD), Statistical Programming, to join a passionate team within Advanced Quantitative Sciences- Development.
Novartis - Senior Principal Statistical Programmer
We have an exciting opportunity for a Senior Principal Statistical Programmer, to join a passionate team within Advanced Quantitative Sciences – Development.
Pierre Fabre - Clinical Development Safety Statistics Expert M/F
We are seeking a highly skilled and proactive Clinical Development Safety Statistics Expert to join our Biometry Department and the Biometry Leadership Team based in Toulouse (31, Oncopole) or Boulogne (92).
Pierre Fabre - Lead Statistician – Real World Evidence -CDI- M/F
Pierre Fabre Laboratories are hiring a highly skilled and experienced Lead Statistician – Real World Evidence (RWE) to join the Biometry Department, part of the Data Science & Biometry Department, based in Toulouse (Oncopôle) or Boulogne.
Pierre Fabre - Lead Statistician- Clinical Trials M/F
We are seeking a highly skilled and experienced Lead Statistician in Clinical Trials to join our Biometry Department based in Toulouse (31, Oncopole) or Boulogne (92).
We are looking for Senior Statistical Programmers in the UK to join Veramed, where you'll deliver high-impact programming solutions in an FSP-style capacity, while advancing your career in a supportive, growth-driven environment.